LENSAR, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
LENSAR, INC. (LNSR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $65.00 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2026-08-13
- LENSAR, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2026-06-30 was $65.00, a 67.98% decline year-over-year.
- LENSAR, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2026-03-31 was $115.00, a 59.51% decline year-over-year.
- LENSAR, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2025-09-30 was $180.00, a 33.82% decline year-over-year.
- LENSAR, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2025-06-30 was $203.00, a 56.44% decline year-over-year.
- LENSAR, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2025 was $837.00, a 45.33% decline from fiscal 2024.
- LENSAR, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2024 was $1531.00, a 32.38% decline from fiscal 2023.
- LENSAR, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $2264.00, a 9.48% decline from fiscal 2022.
- LENSAR, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $2501.00, a 436.70% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $65.00 10-Q · filed 2026-08-13 | $180.00 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $115.00 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | $837.00 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $180.00 10-Q · filed 2025-11-06 | $667.00 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $203.00 10-Q · filed 2025-08-07 | $488.00 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | $284.00 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $1531.00 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $272.00 10-Q · filed 2024-11-07 | $1269.00 10-Q · filed 2024-11-07 | ||
| 2024-06-30 | $466.00 10-Q · filed 2024-08-08 | $1001.00 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | $540.00 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $2264.00 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $655.00 10-Q · filed 2023-11-09 | $2445.00 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | $604.00 10-Q · filed 2023-08-09 | $1794.00 10-Q · filed 2023-08-09 | ||
| 2023-03-31 | $1209.00 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $2501.00 10-K · filed 2024-03-04 | |||
| 2022-09-30 | $461.00 10-Q · filed 2022-11-09 | $2082.00 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | $503.00 10-Q · filed 2022-08-08 | $1050.00 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | $534.00 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $466.00 10-K · filed 2023-03-16 | |||
| 2021-09-30 | $202.00 10-Q · filed 2021-11-08 | $300.00 10-Q · filed 2021-11-08 | ||
| 2021-06-30 | $59.00 10-Q · filed 2021-08-06 | $99.00 10-Q · filed 2021-08-06 | ||
| 2021-03-31 | $40.00 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Apyx Medical Corp (APYX) | United States | $0.120B | -21.85 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B |